Global alignment on biosimilar comparability principles across regions Global Alignment on Biosimilar Comparability Principles Across Regions Biosimilars have emerged as a significant aspect of modern therapeutic development, enabling access to cost-effective biologic treatments. Regulatory Affairs professionals must understand the frameworks surrounding biosimilar comparability, especially concerning process changes. This article will explore the existing guidelines, regulations, and agency expectations spanning the US, UK, and EU, offering a structured manual for navigating the biosimilar comparability protocols. Regulatory Context Biosimilars are designed to be highly similar to approved reference biologics, necessitating rigorous comparability assessments to demonstrate that no clinically meaningful differences exist in…

Comparability strategies for device, container closure and delivery changes Comparability strategies for device, container closure and delivery changes Context Biosimilars are biological products highly similar to an approved reference product. Their development involves stringent regulatory frameworks that ensure their quality, safety, and efficacy. When a biosimilar undergoes changes in manufacturing processes, such as alterations in device, container closure systems, or methods of delivery, regulatory affairs (RA) professionals must determine the appropriate pathways for demonstrating comparability to the reference product. This manual delineates comparability strategies within the context of regulatory expectations as set forth by authorities such as the FDA in…

Governance frameworks for recurring biosimilar comparability assessments Governance frameworks for recurring biosimilar comparability assessments In the evolving landscape of biopharmaceutical development, regulatory affairs (RA) surrounding biosimilars have garnered significant attention, particularly with regard to biosimilar comparability protocols for process changes. This regulatory explainer manual provides a comprehensive overview of the pertinent regulations, guidelines, agency expectations, and strategies essential for managing comparability assessments associated with biosimilar products in the United States, European Union, and the United Kingdom. Context Biosimilars are biologic medical products highly similar to already approved biologics (reference products) in terms of structure, biological activity, safety, and efficacy. The…

Using platform knowledge to streamline comparability for related products Biosimilar Comparability Protocols for Process Changes The development and approval of biosimilars has become increasingly critical within the pharmaceutical landscape, particularly given the rising costs of biologics and the substantial patient population that relies on these therapies. A crucial component of the regulatory strategy for biosimilars involves the development of comparability protocols, particularly in relation to process changes that may occur after initial approval. This article provides a comprehensive overview of the regulations and guidelines governing biosimilar comparability protocols in the context of process changes, drawing on the expectations of regulatory…

Inspection readiness for biosimilar comparability documentation and evidence Inspection Readiness for Biosimilar Comparability Documentation and Evidence The development and approval of biosimilars present unique regulatory challenges, particularly concerning comparability protocols for process changes. These concerns necessitate a deep understanding of regulatory frameworks and agency expectations in different jurisdictions, notably the United States (FDA), European Union (EMA), and the United Kingdom (MHRA). This article aims to provide a comprehensive regulatory explainer manual for professionals in the pharmaceutical and biotech sectors, focusing on the essential components of biosimilar comparability documentation and processes. Context Biosimilars are biologic medical products highly similar to reference…